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ABSTRACT 
Background: The K3326X variant in BRCA2 (BRCA2*c.9976A>T; p.Lys3326*; rs11571833) 
has been found to be associated with small increased risks of breast cancer and other cancers 
such as lung and upper aero-digestive tract in recent studies. However, it is not clear to what 
extent linkage disequilibrium with fully pathogenic mutations might account for this association. 
There is scant information about the effect of K3326X in other hormone-related cancers.   
Methods: Using weighted logistic regression, we analyzed data from the large iCOGS study 
including 76,637 cancer cases and 83,796 controls to estimate the association of K3326X with 
breast, ovarian, and prostate cancer risks independent of known pathogenic variants. Using Cox 
proportional hazards modeling, we also examined the associations of K3326X with breast and 
ovarian cancer risks among 7,183 BRCA1 variant carriers.  
Results: The K3326X variant was associated with breast (OR=1.28; 95% CI: 1.17-1.40; 
p=4.6x10-6) and invasive ovarian cancer (OR=1.26; 95% CI: 1.10-1.43; p=4.0x10-3). These 
associations were stronger for serous ovarian cancer and for estrogen receptor-negative breast 
cancer (OR=1.46; 95%CI: 1.25-1.70; p=3.7x10-5 and OR=1.50; 95% CI: 1.27-1.75; p = 2.4x10-5, 
respectively). For BRCA1 mutation carriers, there was a significant inverse association of the 
K3326X variant with risk of ovarian cancer but no association with breast cancer. No association 
with prostate cancer was observed.  
Conclusions: Our study provides evidence that the K3326X variant is associated with risk of 
developing breast and ovarian cancers independent of other pathogenic variants in BRCA2. 
Further studies are needed to determine the biological mechanism of action responsible for these 
associations.  
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INTRODUCTION 
Inheritance of a pathogenic variant in BRCA2 is one of the strongest risk factors for 
breast and ovarian cancers [1-4]. Estimates of the cumulative risk by age 70 years in BRCA2 
variant carriers are 45% for breast cancer and 11% for ovarian cancer [5, 6]. BRCA2 variants 
have also been shown to increase risk of prostate cancer [7-9], with the lifetime risk of prostate 
cancer in BRCA2 variant carriers estimated in the range of 19% - 34% [9]. In some studies, 
carriers of BRCA2 pathogenic variants also had increased risks of several other cancers, 
including pancreatic cancer [7, 8, 10, 11], stomach cancer, and malignant melanoma [7]. 
BRCA2*c.9976A>T; p.Lys3326*, hereafter referred to as K3326X, is a stop-gain variant 
in the coding region of BRCA2. It arises from a substitution of thymidine for adenine at 
nucleotide 9976 of the BRCA2 coding sequence, and results in loss of the final 93 amino acids of 
the BRCA2 protein. This premature stop codon was first described in 1996 by Mazoyer et al. 
[12] who found a minor allele frequency of about 1% in the control population and no increased 
prevalence of this sequence variant in patients with breast cancer, although the study was small, 
with 462 controls and 513 cases. The K3326X variant has been identified through linkage 
disequilibrium (LD) in individuals with various types of cancers, either alone or in combination 
with known pathogenic variants in BRCA2 [13-15]. Recent genome-wide association studies 
have identified the association between the K3326X variant and risk of squamous-cell lung 
cancer [16] and breast cancer [17] at genome-wide significance levels, with odds ratios of 2.47 
(P = 4.7x10-20) and 1.26 (P = 4.9x10-8), respectively. Recently, a large pooled case-control study 
of cancers of the upper aero-digestive tract (UADT, including esophageal cancer) and the 
K3326X variant found that the K3326X variant was associated with UADT cancers (OR = 2.53; 
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95% CI: 1.89-3.38) [18] as well, with a particularly strong effect for esophageal cancer (OR = 
3.30; p = 3x10-4).  
K3326X is in LD with the pathogenic variants BRCA2*c.6275_6276delTT (formerly 
reported as 6503-6504delTT) [12, 14] and BRCA2*c.9257-16T>C (formerly reported as IVS 24-
17T>C) [19]. It is unclear therefore to what extent the association of the K3326X variant with 
cancer is due to its own functional impact or because it is in LD with other BRCA2 pathogenic 
variants. In this study, we therefore analyzed the association of the BRCA2 K3326X sequence 
variant with respect to risk of breast cancer independently from its association with known 
BRCA2 pathogenic variants, and for the first time examined the association between K3326X 
and ovarian and prostate cancer. We further assessed whether K3326X is an independent 
modifier of breast, and ovarian cancer risk in BRCA1 pathogenic variant carriers.  
METHODS 
This study used data from the four consortia within the Collaborative Oncological Gene-
Environment Study (COGS): the Consortium of Investigators of Modifiers of BRCA1/2 
(CIMBA), the Breast Cancer Association Consortium (BCAC), the Ovarian Cancer Association 
Consortium (OCAC), and the PRostate cancer AssoCiation group To Investigate Cancer 
Associated aLterations in the genome (PRACTICAL). The COGS central focus was using data 
from high throughput genotyping of large epidemiological studies, with state-of-the-art analysis 
and mathematical models to combine data on genetic and environmental/life style risk factors  
[20]. Details on the numbers of participants in each consortium are shown in Table 1. To 
validate the effect of the BRCA2 K3326X variant on ovarian cancer risk, we sequenced the 
BRCA2 gene in an independent sample of ovarian cancer cases and controls.  
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 Statistical methods: 
Fisher’s exact statistics were calculated to assess associations between the K3326X 
variant and known BRCA2 pathogenic variants among study subjects in CIMBA. Using the 
datasets from the BCAC, OCAC, and PRACTICAL consortia, we evaluated the association of 
the BRCA2 K3326X variant with risks of breast, invasive ovarian, and prostate cancer, 
respectively, through logistic regression models with adjustment for attained age, consortium 
study site, and principal components of population structure. To examine the hypothesis that 
K3326X is associated with breast and ovarian cancers independently from BRCA2 pathogenic 
variants, we calculated and compared odds ratios using weighted logistic regression models (i.e., 
ORw), described below, and odds ratios using un-weighted logistic regression models (i.e., OR) 
using Wald Z-statistics. Because of the lack of BRCA2 status in the BCAC and OCAC datasets, 
to account for possible LD with BRCA2 pathogenic variants, we developed a model using the 
CIMBA dataset to predict whether cases and controls were carriers of pathogenic BRCA2 
variants based on age at diagnosis (for cases) and age at interview (for controls) and carrier status 
at K3326X. We then used this model to predict the probability of not having a pathogenic 
BRCA2 variant in the other datasets and used this as the weight in the logistic regression model. 
This weight allowed us to adjust for the contribution of each patient to the test statistics based on 
their probability of not having a pathogenic BRCA2 variant. Details of the calculation of these 
weights are shown in the Appendix. The association of the K3326X variant with breast cancer 
risk by ER status, triple-negative status, and tumor morphology, specifically ductal and lobular, 
were estimated using a similar approach but restricting the case samples to ER+, ER-, triple-
negative (ER, PR, and HER2 negative), ductal, and lobular, respectively. The association of the 
K3326X variant with ovarian cancer risk by histological subtypes of ovarian cancer, specifically 
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serous, mucinous, endometrioid, and clear cell, were estimated by restricting the case samples to 
these respective histologies. We also examined differences between the odds ratio estimates 
using Z-statistics to determine whether or not the magnitude of the associations between the 
K3326X variant and breast cancer risk were statistically different across breast and ovarian 
cancer subtypes. Using the datasets from the CIMBA consortium and Cox proportional hazards 
model, we examined the associations of the K3326X variant with breast and ovarian cancer risks 
for BRCA1 pathogenic variant carriers with censoring as defined in other CIMBA consortium 
analyses of data from the iCOGS study [21]. To account for the inclusion of multiple carriers 
from the same family, a robust variance approach clustering on family membership was used  
[22]. Statistical analyses were performed in R (version 2.14.2) [23]. All statistical tests were two 
sided.  
Homology directed repair (HDR) assay: 
 The HDR assay for BRCA2 has been described previously by Guidugli et al (2013) [24]. 
Full-length Flag-BRCA2 wild-type and mutant expression constructs were co-transfected with an 
I-Sce1 expressing pcBASce plasmid into BRCA2 deficient V-C8 cells, stably expressing the 
DR-GFP reporter plasmid. HDR-dependent DNA double strand break was quantified by 
fluorescence-activated cell sorting (FACS) of GFP positive cells after 72 hours. Equivalent 
expression of wild-type and mutant BRCA2 proteins was confirmed by western blot analysis of 
anti-Flag-M2 (Sigma F1804) antibody immunoprecipitates from V-C8 cell lysates. 
RESULTS 
Table 2 shows the frequencies of the two most frequent BRCA2 pathogenic variants 
(c.6275_6276delTT and c.4889C>G) among K3326X variant carriers in CIMBA. The 
11 
 
c.6275_6276delTT known pathogenic variant was identified in 233/306 K3326X variant carrier 
families carrying the K3326X variant and in 5/4795 K3326X variant non-carrier families, and 
c.4889C>G was observed in 9/306 K3326X variant positive families and 0/4795 K3326X variant 
non-carrier families. The list and frequency of all pathogenic variants in the BRCA2 gene that co-
occurred with the K3326X variant in CIMBA are shown in Supplemental Table 1. Within the 
BCAC dataset, among K3326X variant carriers, 1471 of 1490 individuals also harbored the 
BRCA2*c.9257-16T>C variant, which was not considered pathogenic based on the low 
likelihood for splice site alteration [13]. Within the OCAC dataset, among K3326X variant 
carriers, all K3326X variant carriers also carried the BRCA2*c.9257-16T>C variant. Within the 
independently sequenced set of ovarian cancer cases and controls, 2240 ovarian cancer cases and 
1530 controls were included. Twenty-seven K3326X carriers were found in the controls 
compared to 48 in the cases (OR = 1.23 (95% CI: 0.7-2.0)) and three of these carriers (all cases) 
also carried the BRCA2*c.6275_6276delTT pathogenic variant. Functional analyses showed that 
the K3326X variant had only a slight reduction in DNA repair compared to wild-type and 
significantly different compared to the known pathogenic BRCA2 variants. 
Association between the K3326X variant and breast cancer risk in BCAC and CIMBA: 
Previous principal component analyses of these data derived six components used as 
adjustments for population structure in logistic regression models [17]. The analyses of K3326X 
and breast cancer are shown in Table 3. Of note, the odds ratios adjusted for potential LD with 
known pathogenic BRCA2 variants were only slightly attenuated (e.g. from 1.31 to 1.28 for all 
invasive breast cancer). The weighted odds ratios were statistically different between ER- and 
ER+ breast cancer data subsets (p = 0.03) but not between triple negative and ER+ breast cancer 
data subsets (p = 0.22) (data not shown). There was no evidence that K3326X was associated 
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with lobular breast cancer (p = 0.69), but the sample size of lobular breast cancer cases among 
the K3326X variant carriers was relatively small (n = 67), and the association between K3326X 
and breast cancer was not statistically different between participants with ductal and lobular 
tumors (p = 0.13). No association with breast cancer risk for BRCA1 pathogenic variant carriers 
was observed (HR = 1.00; 95% CI: 0.78, 1.29). 
Association between the K3326X variant and ovarian cancer risk: 
Previous principal component analyses derived five components used as adjustments for 
population structure in logistic regression models [25]. Adjusted weighted and unweighted ORs 
by histologic subtype of ovarian cancer are presented in Table 4. The K3326X variant was 
present in 323 of 14542 individuals (2.22%) with invasive ovarian cancer (OR = 1.29 (95% CI: 
1.13, 1.46); ORw = 1.26 (95% CI: 1.10-1.43)) compared to 1.78% of controls. A significant 
association of K3326X was observed with serous ovarian cancer (ORw = 1.46; 95% CI: 1.25-
1.70). However, little evidence was seen for an association of K3326X with non-serous ovarian 
cancer, although the sample size of such cancer cases among the K3326X variant carriers was 
small (n = 60). In contrast, among BRCA1 carriers, a significant decreased risk for K3326X 
variant carriers versus non-carriers was observed (HR = 0.43; 95% CI: 0.22-0.84). 
Association between the K3326X variant and prostate cancer risk: 
Previous principal component analyses derived six components used as adjustments for 
population structure in logistic regression models [26]. The K3326X variant was present in 358 
of 21,014 cases (1.70%) compared to 364 of 21,992 controls (1.66%) (OR = 0.92 (95% CI: 0.77-
1.09); ORw = 0.90 (95% CI: 0.76-1.07)). We estimated that this study had 87.6% power to detect 
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an odds ratio of 1.25 using a two-sided test, assuming that 1.7% of the population are K3326X 
carriers. 
DISCUSSION 
In this study, we confirmed that the BRCA2 K3326X variant is associated with increased 
risk of breast cancer independent of additional BRCA2 pathogenic variants and demonstrated an 
even stronger association with serous ovarian cancer. These results suggest a role for the 
K3326X variant in both breast and ovarian cancers etiology but not in prostate cancer etiology.  
The prevalence of K3326X in control populations (1.7%) is consistent with the observed 
allele frequency of the K3326X variant in the European population reported by the International 
HapMap Consortium [27]. More recent data [Exome Aggregation Consortium (ExAC), 
Cambridge, MA (URL: http://exac.broadinstitute.org) [accessed February, 2015)] found the 
variant in 609/33,749 (1.8%) non-Finnish European sequenced individuals and a carrier 
frequency of 2.4% in Finland. In our study, most K3326X carriers also carried the 
BRCA2*c9257-16T>C variant, which is also consistent with previous studies [13, 19]. However, 
most individuals with BRCA2 pathogenic variants do not carry the K3326X variant, with the 
exception of individuals with c.6275_6276delTT and c.4889C>G variants (Table 2).  
The odds ratios obtained from unweighted logistic regression and weighted logistic 
regression were similar, suggesting that K3326X is associated with the risk of developing breast 
and ovarian cancers independently from BRCA2 known pathogenic variants (Table 3 and 4). 
The association of the K3326X variant with cancer risk was strongest in patients with triple 
negative breast and serous ovarian tumors (OR = 1.51 (95% CI: 1.18, 1.92) and 1.46 (95% CI: 
1.25, 1.70), respectively). Our results, together with evidence of molecular commonalities 
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between triple negative breast and high-grade serous ovarian tumors [28], suggest a possible 
related etiology between these two tumor subtypes.  
The K3326X variant was associated with the risk of ER- and triple-negative breast cancer 
by a greater magnitude than with the risk of ER+ breast cancer (Table 3). This association was 
more significant in participants with ER- than in those with ER+ tumors (p = 0.03). We did not 
detect a significant difference between the association of the K3326X variant in participants with 
triple negative and ER+ tumors (p = 0.22), but the number of participants carrying the K3326X 
variant among triple negative tumors was small (n = 53). ER negative and triple negative status 
has been linked to BRCA1 variants but not BRCA2 variants. BRCA1-related breast cancers are 
more likely to be ER- than are non-BRCA1-related breast cancers and BRCA2-related breast 
cancers [29, 30]. Most BRCA1-related breast cancers are also progesterone receptor (PR) and 
human epidermal growth factor receptor (HER) 2 negative (i.e. triple-negative) [29, 31-36]. 
Because of these findings, BRCA1 tumors were hypothesized to have a different hormone-
independent mechanism than BRCA2 tumors [34]. Further studies are needed to understand the 
association of the K3326X variant on breast cancer risk in individuals with ER- and ER+ tumors.  
Women carrying the K3326X variant had significantly higher risk of ovarian cancer. This 
association was shown in both the OCAC dataset and the full sequenced dataset; however, the 
independently sequenced set is too small to provide reliable odds ratio. The K3326X variant was 
significantly associated with risk of serous ovarian cancer but not mucinous, endometrioid, or 
clear cell ovarian cancer (Table 4). This finding is consistent with epidemiological and genetic 
data showing that serous tumors have a different etiology from other ovarian carcinomas [37-39]. 
It is of interest that the associations of K3326X with cancer risks were stronger in ER- breast 
cancer and in serous ovarian cancer, both of which are associated with BRCA1 pathogenic 
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variants, while breast tumors of BRCA2 pathogenic variants carriers tend to be ER+ breast 
cancers [34].  
Our study also provides other interesting findings that warrant further investigation. First, 
the K3326X variant is associated with increased risks of breast and ovarian cancer in the general 
population; however, in BRCA1 variant carriers, the K3326X variant is inversely associated with 
risk of ovarian cancer and not with risk of breast cancer. Second, our study found no association 
between the K3326X variant and prostate cancer risk, in contrast to the increased risk of prostate 
cancer in carriers of BRCA2 pathogenic variants [44-47]. The difference between the risk 
associations of K3326X and known BRCA2 pathogenic variants has been observed previously. 
Wang et al (2014) reported a more than two-fold increased squamous-cell lung carcinoma risk in 
K3326X variant carriers [16]; however, to date, there has been no evidence of any altered risk of 
lung cancer in families carrying BRCA2 pathogenic variants [8, 40, 41]. Additional studies are 
required to analyze the discrepant risk associations of the K3326X variant and other known 
BRCA2 pathogenic variants with prostate and lung cancer risks and whether the K3326X variant 
may have an association with cancer risk independent of other genes. In contrast to lung cancer, 
there have been some reports of carriers of BRCA2 pathogenic variants having increased risk of 
some UADT cancers [40, 41].  
We can only speculate about how K3326X might affect key functions of the BRCA2 
protein. Fanconi anemia is an autosomal recessive disease characterized by cancer susceptibility, 
cellular hypersensitivity to DNA cross-linking agents, and other conditions [42]. FANCD2 
encodes the protein for Fanconi anemia group D2, and is monoubiquitinated in response to DNA 
damage [43]. Interaction of monoubiquitinated FANCD2 and BRCA2 is essential for activation 
of the homologous recombination activity of RAD51, an important enzyme involved in DNA 
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repair mechanisms, and for loading onto the damaged DNA [44-49]. Cells that express BRCA2 
protein lacking the C terminal exon 27 coding region do not show co-localization of FANCD2, 
BRCA2, and RAD51 on chromatin [44, 49]; mice with deletions of exon 27 and FANCD2 
knockout mice had increased susceptibility to various types of cancers [50]. We hypothesize that 
the K3326X variant modifies breast and ovarian cancer risk by altering the C terminus of 
BRCA2, resulting in loss of the interaction between FANCD2 and BRCA2 and thus, inactivating 
RAD51. However, in the functional assay testing the ability of various BRCA2 cell constructs to 
repair double-strand DNA breaks by homologous recombination, there was a slight reduction in 
DNA repair activity for the K3326X variant compared to the wild-type and quite distinct from 
the known pathogenic BRCA2 variants. Additional functional analyses on the K3326X variant 
are needed to demonstrate the role of the K3326X variant on the BRCA2 protein. 
 Our study is the largest study to date examining the association of the BRCA2 K3326X 
variant and breast, ovarian, and prostate cancer risks. The large sample size and the use of 
weighted logistic regression models allowed us to estimate the underlying association of 
K3326X with cancer risk independent of known BRCA2 pathogenic variants. A limitation of our 
analysis was the lack of BRCA2 status in the BCAC and OCAC datasets resulting in our use of 
the CIMBA BRCA2 dataset to calculate the probability of BRCA2 in order to create weights for 
the logistic regression models. As shown in tables 3 and 4, the effect of LD between K3326X 
and two BRCA2 pathogenic variants (i.e. c.6275_6276delTT and c.4889C>G) was quite small 
and did not materially change the results.  
In conclusion, our study provides evidence that the BRCA2*c.9976A>T (K3326X) 
variant contributes to the risk of developing breast and ovarian cancers. It remains open whether 
the underlying mechanism for this association is identical to that for lung and UADT cancers; it 
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is unlikely that this question can be resolved using genetic data alone. Additional functional 
studies will be needed to determine the biological mechanism of action of the K3326X variant in 
the diverse set of cancers associated with it.  
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Table 1: Number of controls and breast cancer (BC), ovarian cancer (OC) and prostate cancer (PC) cases included in the analysis. 
Study Included in the Analysis 
CIMBA (The Consortium of Investigators of Modifiers 
of BRCA1/2) [51] 
- 7183 BRCA1 mutation carriers, of which 1658 were unaffected, 2497 were 
breast cancer cases, 543 were ovarian cancer cases, and 267 had both breast 
and ovarian cancer. 
- 5101 BRCA2 mutation carriers, of which 2183 were unaffected, 2538 were 
breast cancer cases, 240 were ovarian cancer cases, and 140 had both breast 
and ovarian cancer. 
BCAC (Breast Cancer Association Consortium) [52] 41081 breast cancer cases and 38693 female controls 
OCAC (Ovarian Cancer Association Consortium) [53] 14542 invasive ovarian cancer cases and 23111 female controls 
PRACTICAL (Prostate cancer AssoCiation group To 
Investigate Cancer Associated aLterations in the 
genome) [54] 
21014 prostate cancer cases and 21992 male controls 
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Table 2: Frequencies of the two most frequent BRCA2 pathogenic variants that co-occurred with the K3326X common variant in 
CIMBA. 
HGVS Nomenclature BRCA2 K3326X non-carriers BRCA2 K3326X carriers  
c.6275_6276delTT 5 233 p < 0.0011 
c.4889C>G 0 9 p <0.0011 
Other BRCA2 known pathogenic variants2 4790 64 Reference 
1P-values from Fisher’s exact tests calculated to assess the association between the K3326X variant and known BRCA2 pathogenic 
variants. Each family in CIMBA was counted only once in this analysis. 
2Listed in Supplementary Table 1. 
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Table 3: Association between BRCA2 K3326X variant and risk of breast cancer by tumor subtypes; 38693 controls, of which 637 were 
K3326X carriers; Breast Cancer Association Consortium. 
Subtypes Number 
of cases 
Number of K3326X 
carriers in cases 
OR (95% CI)1 P-values for 
OR 
Weighted ORw 
(95% CI)1,2 
P-values for 
ORw 
All invasive 41081 852 1.31 (1.20, 1.43) 6.05x10-7 1.28 (1.17, 1.40) 4.55x10-6 
   ER- 6441 158 1.54 (1.31, 1.79) 5.07x10-6 1.50 (1.27, 1.75) 2.44 x10-5 
   ER+ 24833 501 1.28 (1.15, 1.42) 8.50x10-5 1.25 (1.13, 1.36) 3.45x10-4 
   Triple Negative 2158 53 1.55 (1.22, 1.96) 2.45x10-3 1.51 (1.18, 1.92) 4.45x10-3 
   Ductal  21490 466 1.33 (1.20, 1.48) 3.38x10-6 1.30 (1.17, 1.44) 1.77x10-5 
   Lobular  3752 67 1.07 (0.87, 1.32) 0.57 1.05 (0.85, 1.29) 0.69 
1Adjusted for attained age (at interview for controls and at diagnosis for cases), principal components of European population 
structure, and study site. 
2Calculated using weighted logistic regression models. The weight applied for the ith individual in the BCAC dataset is (1 - Probability 
of K3326X carriage and harboring known pathogenic variants in BRCA2) 
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Table 4: Association between BRCA2 K3326X variant and risk of ovarian cancer by histological subtype; 23111 controls, of which 
411 were K3326X variant carriers; Ovarian Cancer Association Consortium. 
Subtype Number of 
cases3 
Number of K3326X 
carriers in cases 
OR (95% CI)1 P values for 
OR 
Weighted ORw  
(95% CI)1,2 
P-values for 
ORw 
All Invasive 14514 322 1.29 (1.13, 1.46) 1.41x10-3 1.26 (1.10, 1.43) 4.03x10-3 
   Serous  8360 210 1.50 (1.29, 1.74) 9.21x10-6 1.46 (1.25, 1.70) 3.66x10-5 
   Non-serous 4031 60 0.83 (0.65, 1.04) 0.18 0.81 (0.63, 1.02) 0.14 
   Mucinous 943 16 0.93 (0.59, 1.39) 0.79 0.91 (0.58, 1.37) 0.72 
   Endometrioid 2066 31 0.82 (0.59, 1.11) 0.31 0.81 (0.58, 1.09) 0.27 
   Clear Cell 1022 13 0.72 (0.44, 1.12) 0.26 0.71 (0.42, 1.10) 0.23 
1Adjusted for attained age (at interview for controls and at diagnosis for cases), principal component of European population structure, 
and study site. 
2Calculated using weighted logistic regression models. The weight applied for the kth individual in the OCAC dataset is (1 - 
Probability of K3326X carriage and harboring known pathogenic variants in BRCA2) 
3In total, 2129 cases did not have information on ovarian cancer histologic type.
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APPENDIX 
Calculated weights: 
Probability of BRCA2 pathogenic variant carriers also carrying the K3326X variant (i.e. 
P(K3326X|BRCA2)) was calculated using the following formula: 
P(K3326X|𝐵𝑅𝐶𝐴2) =  # 𝐵𝑅𝐶𝐴2 𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠 𝑎𝑙𝑠𝑜 ℎ𝑎𝑟𝑏𝑜𝑟 𝐾3326𝑋# 𝐵𝑅𝐶𝐴2 𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠  
Applying the above formula to CIMBA dataset, we obtained P(K3326X|BRCA2) = 
306/5101 = 0.060. Probability of K3326X variant carriers not harboring known pathogenic 
variants in BRCA2 (i.e. P(K3326X| not BRCA2)) were calculated using the following formula: 
P(K3326X|not 𝐵𝑅𝐶𝐴2) =  # 𝐵𝑅𝐶𝐴2 𝑛𝑜𝑛𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠 ℎ𝑎𝑟𝑏𝑜𝑟 𝐾3326𝑋# 𝐵𝑅𝐶𝐴2 𝑛𝑜𝑛𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠  
Applying the above formula to the BCAC control-only subset, we obtained P(K3326X| 
not BRCA2) = 637/38693 = 0.016. Applying the above formula to the OCAC control-only 
subset, we obtained P(K3326X| not BRCA2) = 408/23266 = 0.018. We assumed that probability 
of being a BRCA2 carrier (i.e. P(BRCA2)) for each case and control in the BCAC and OCAC 
datasets was equal to the age-specific relative risk estimated by Antoniou et al (2003) based on a 
meta-analysis of BRCA2 positive families identified through population-based studies of breast 
and ovarian cancer (Antoniou et al, 2003). Probability of K3326X carriers harboring known 
pathogenic variants of BRCA2 was calculated using Bayes’ theorem:  
P(𝐵𝑅𝐶𝐴2|K3326X)
=  𝑃(𝐾3326𝑋|𝐵𝑅𝐶𝐴2) ∗ 𝑃(𝐵𝑅𝐶𝐴2)
𝑃(𝐾3326𝑋|𝐵𝑅𝐶𝐴2) ∗ 𝑃(𝐵𝑅𝐶𝐴2) + 𝑃(𝐾3326𝑋|𝑛𝑜𝑡𝐵𝑅𝐶𝐴2) ∗ 𝑃(𝑛𝑜𝑡 𝐵𝑅𝐶𝐴2) 
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The weight applied for the ith case in the BCAC dataset in the logistic regression model 
was: 
w𝑖 = 1 −  P(𝐵𝑅𝐶𝐴2|K3326X)𝑖 =  1 −  0.060 ∗ 𝑃(𝐵𝑅𝐶𝐴2)𝑖0.060 ∗ 𝑃(𝐵𝑅𝐶𝐴2)𝑖 + 0.016 ∗ (1 − 𝑃(𝐵𝑅𝐶𝐴2)𝑖) 
The weight applied for the jth control in the BCAC dataset in the logistic regression 
model was: 
w𝑗 = 1 −  P(𝐵𝑅𝐶𝐴2|K3326X)𝑗 =  1 −  0.940 ∗ 𝑃(𝐵𝑅𝐶𝐴2)𝑗0.940 ∗ 𝑃(𝐵𝑅𝐶𝐴2)𝑗 + 0.016 ∗ (1 − 𝑃(𝐵𝑅𝐶𝐴2)𝑗) 
The weight applied for the kth case in the OCAC dataset in the logistic regression model 
was: 
w𝑘 = 1 −  P(𝐵𝑅𝐶𝐴2|K3326X)𝑘 =  1 −  0.060 ∗ 𝑃(𝐵𝑅𝐶𝐴2)𝑘0.060 ∗ 𝑃(𝐵𝑅𝐶𝐴2)𝑘 + 0.018 ∗ (1 − 𝑃(𝐵𝑅𝐶𝐴2)𝑘) 
The weight applied for the lth control in the OCAC dataset in the logistic regression 
model was: 
w𝑙 = 1 −  P(𝐵𝑅𝐶𝐴2|K3326X)𝑙 =  1 −  0.940 ∗ 𝑃(𝐵𝑅𝐶𝐴2)𝑙0.940 ∗ 𝑃(𝐵𝑅𝐶𝐴2)𝑙 + 0.018 ∗ (1 − 𝑃(𝐵𝑅𝐶𝐴2)𝑙) 
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